吲达帕胺分别联用3种降压药治疗2级原发性高血压的疗效和安全性比较 点击下载
| 论文标题： | 吲达帕胺分别联用3种降压药治疗2级原发性高血压的疗效和安全性比较 |
| 英文标题： | |
| 中文摘要： | 目的：比较吲达帕胺分别联合贝那普利、厄贝沙坦、氨氯地平治疗2级原发性高血压（EH）的疗效和安全性。方法：150例2级EH患者随机分为贝那普利组（50例）、厄贝沙坦组（50例）和氨氯地平组（50例）。3组患者均给予吲达帕胺片2.5 mg，口服，每日1次。在此基础上，贝那普利组患者口服盐酸贝那普利片10 mg，每日1次；厄贝沙坦组患者口服厄贝沙坦片150 mg，每日1次；氨氯地平组患者口服氨氯地平片5 mg，每日1次。3组疗程均为12周。观察3组患者治疗前后收缩压、舒张压、心率、总胆固醇（TC）、三酰甘油（TG）、血钾水平及不良反应发生情况。结果：贝那普利组、厄贝沙坦组和氨氯地平组患者总有效率比较，差异无统计学意义（90.0％ vs. 88.0％ vs. 92.0％，P＞0.05）。治疗前，3组患者收缩压、舒张压、心率、TC、TG、血钾水平比较，差异均无统计学意义（P＞0.05）。治疗后，3组患者收缩压、舒张压均显著低于同组治疗前，差异均有统计学意义（P＜0.05）；但3组间比较差异均无统计学意义（P＞0.05）。3组患者治疗前后心率、TC、TG及贝那普利组、厄贝沙坦组治疗前后血钾比较，差异均无统计学意义（P＞0.05）。氨氯地平组患者血钾水平显著低于同组治疗前，差异有统计学意义（P＜0.05）。厄贝沙坦组患者不良反应发生率显著低于贝那普利组和氨氯地平组，差异有统计学意义（P＜0.05），但贝那普利组与氨氯地平组间比较，差异无统计学意义（P＞0.05）。结论：吲达帕胺分别联合贝那普利、厄贝沙坦、氨氯地平治疗2级EH的疗效相当，但厄贝沙坦组的安全性优于贝那普利组和氨氯地平组。 |
| 英文摘要： | OBJECTIVE： To compare therapeutic efficacy and safety of indapamide separately combined with benazepril， irbesartan or amlodipine for grade 2 essential hypertension （EH）. METHODS： A total of 150 patients with grade 2 EH were randomly divided into benazepril group （50 cases）， irbesartan group （50 cases） and amlodipine group （50 cases）. 3 groups were given Indapamide tablet 2.5 mg orally， once a day. Benazepril group was additionally given Benazepril hydrochloride tablet 10 mg orally， once a day； irbesartan group was additionally given Irbesartan tablet 150 mg orally， once a day； amlodipine group was additionally given Amlodipine tablet 5 mg orally， once a day. 3 groups were treated for 12 weeks. The levels of systolic pressure， diastolic pressure， heart rate，total cholesterol （TC）， three triacylglycerol （TG） and serum potassium as well as the occurrence of ADR were observed in 3 groups before and after treatment. RESULTS： The total response rate of berazopril group，irbesartar group and a mloelipire group had no significant difference （90.0％ vs. 88.0％ vs. 92.0％，P＞0.05）. There were no statistical significances in the levels of systolic pressure， diastolic pressure， heart rate， TC， TG and serum potassium among 3 groups before treatment （P＞0.05）. After treatment， systolic pressure and diastolic pressure of 3 groups were significantly lower than before， with statistical significance （P＜0.01）； but there was no statistical significance among 3 groups （P＞0.05）. There were no statistical significance in heart rate，TC，TG of 3 groups before and after treatment and the level of serum potassium in benazepril group and irbesartan group （P＞0.05）. After treatment， the level of serum potassium in amlodipine group was significantly lower than before， with statistical significance （P＜0.05）. The incidence of ADR in irbesartan group was significantly lower than benazepril group and amlodipine group， with statistical significance （P＜0.05）； but there was no statistical significance between benazepril group and amlodipine group （P＞0.05）. CONCLUSIONS： The indapamide separately combined with benazepril， irbesartan or amlodipine have similar therapeutic efficacy for grade 2 EH， but the safety of irbesartan is better than those of benazepril and amlodipine. |
| 期刊： | 2017年第28卷第21期 |
| 作者： | 杨红芳，程昌盛，程冬瑀 |
| 英文作者： | YANG Hongfang，CHENG Changsheng，CHENG Dongyu |
| 关键字： | 吲达帕胺；贝那普利；厄贝沙坦；氨氯地平；原发性高血压；疗效；安全性 |
| KEYWORDS： | Indapamide； Benazepril； Irbesartan； Amlodipine； Essential pressure； Therapeutic efficacy； Safety |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！